Moteur de recherche d’entreprises européennes
Financement de l’UE (183 455 €) : Palladium catalyzed C(sp3)‒H late-stage diversification of biologically active molecules Hor01/03/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Palladium catalyzed C(sp3)‒H late-stage diversification of biologically active molecules
Aliphatic amines are central to the function of many biologically active molecules as evidenced by their prevalence in a large number of pharmaceutical agents. The groups appended to these nitrogen atoms are crucial in determining the physical properties of the amine and are linked to how well it interacts with a biological target. Despite the apparent simplicity of the aliphatic amine motif, the number of general methods that allow their late-stage functionalization directly on the bioactive compound is surprisingly limited, and so the development of directed catalytic methods remains an important challenge. Metal catalysed C–H activation represents a versatile tool for late-stage functionalization. It mostly relies on directing functional groups to functionalize C–H bonds. Recently, Professor Gaunt at the University of Cambridge has uncovered a new C–H activation mode that enables the conversion of hindered amines into β-lactams and aziridines. The first objective of this proposal aims to directly apply the transformations developed by Gaunt, e.g. carbonylation, aziridination and acetoxylation reactions, to a precise class of drugs that contain the secondary amine motif as central function, i.e. β-adrenergic drugs. The use of the oxidative Pd(II)/(IV) catalytic cycle will then allow the development of a novel fluorination. The second objective relies on a new methodological concept, which seeks to merge palladium catalysis with radical chemistry, opening a route to develop novel perfluoroalkylation, amination and methylation reactions via a new Pd (II)/(III)/(IV) catalytic cycle. Finally, the third aim will be to apply all the methods developed to four important anticancer drugs, in collaboration with the new AstraZeneca oncology unit in Cambridge, to prepare novel analogues for biological testing.
| The Chancellor Masters and Scholars of the University of Cambridge | 183 455 € |
https://cordis.europa.eu/project/id/702462
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : THE University OF Cambridge, Cambridge, Royaume Uni.
Les visualisations de "The Chancellor Masters and Scholars of the University of Cambridge - Financement de l’UE (183 455 €) : Palladium catalyzed C(sp3)‒H late-stage diversification of biologically active molecules"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
